Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Agios Pharmaceuticals, Inc. (AGIO)
P/E ratio as of 2023: -3.52
According to Agios Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.52. At the end of 2022 the company had a P/E ratio of -20.64.
P/E ratio history for Agios Pharmaceuticals, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.52 |
| 2022 | -20.64 |
| 2021 | 1.24 |
| 2020 | -8.92 |
| 2019 | -7.22 |
| 2018 | -7.65 |
| 2017 | -8.46 |
| 2016 | -8.23 |
| 2015 | -20.64 |
| 2014 | -70.50 |
| 2013 | -9.37 |
| 2012 | -36.40 |
| 2011 | -30.86 |